p.106 抽出テキスト

ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J 2024; 45:3789–3800. https://doi.org/10.1093/eurheartj/ehae479 881. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med 2023;389:975–86. https://doi.org/10.1056/NEJMoa2304968 882. Vukadinovic D, Abdin A, Emrich I, Schulze PC, von Haehling S, Bohm M. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. Clin Res Cardiol 2023;112:954–66. https://doi.org/10.1007/s00392-023-02207-2 883. Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF. Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail 2023;25:528–37. https://doi.org/10.1002/ ejhf.2810 884. Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail 2023;10:1473–80. https:// doi.org/10.1002/ehf2.14310 885. Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. JAMA 2025;333:1965–76. https://doi. org/10.1001/jama.2025.3833 886. Anker SD, Karakas M, Mentz RJ, Ponikowski P, Butler J, Khan MS, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med 2025;31:2640–6. https://doi. org/10.1038/s41591-025-03671-1 887. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210–19. https://doi.org/10.1056/NEJMoa1214865 888. Bhatia K, Sabharwal B, Gupta K, Lopez PD, Kaur A, Bhatia HK, et al. Clinical outcomes of intravenous iron therapy in patients with heart failure and iron deficiency: meta-analysis and trial sequential analysis of randomized clinical trials. J Cardiol 2024;83:105–12. https://doi.org/10.1016/j.jjcc.2023.06.012 889. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37: 2768–801. https://doi.org/10.1093/eurheartj/ehw211 890. Rakisheva A, Farmakis D, Attanasio A, Genis AB, Cohen-Solal A, Gulati G, et al. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors: a clinical consensus statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. Eur J Heart Fail 2025;27:2084–99. https://doi.org/10.1002/ejhf.3753 891. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31: 171–90. https://doi.org/10.1016/j.annonc.2019.10.023 892. Canepa M, Franssen FME, Olschewski H, Lainscak M, Bohm M, Tavazzi L, et al. Diagnostic and therapeutic gaps in patients with heart failure and chronic obstructive pulmonary disease. JACC Heart Fail 2019;7:823–33. https:// doi.org/10.1016/j.jchf.2019.05.009 893. Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Pinilla JMG, Nyolczas N, et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail 2018;20:100–10. https://doi.org/10. 1002/ejhf.964 894. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013;34:2795–803. https://doi.org/10.1093/eurheartj/eht192 895. Magnussen H, Canepa M, Zambito PE, Brusasco V, Meinertz T, Rosenkranz S. What can we learn from pulmonary function testing in heart failure? Eur J Heart Fail 2017;19:1222–29. https://doi.org/10.1002/ejhf.946 896. Becher PM, Lindberg F, Benson L, Hage C, Dahlstrom U, Rosenkranz S, et al. Phenotyping patients with chronic obstructive pulmonary disease and heart failure. ESC Heart Fail 2024;12:900–11. https://doi.org/10.1002/ehf2. 15127 897. Paolillo S, Dell’Aversana S, Esposito I, Poccia A, Perrone Filardi P. The use of beta-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med 2021;88:9–14. https://doi. org/10.1016/j.ejim.2021.03.035 898. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977–84. https://doi.org/10.1136/thoraxjnl-2012-201945 899. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a doubleblind randomised controlled trial. Lancet 2016;387:1817–26. https://doi. org/10.1016/S0140-6736(16)30069-1 900. Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart 2017;103:1536–42. https://doi.org/10.1136/heartjnl-2016-310897 901. Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med 2018;6:368–78. https://doi.org/10.1016/S2213- 2600(18)30054-7 902. Cowie MR, Gallagher AM. Sleep disordered breathing and heart failure: what does the future hold? JACC Heart Fail 2017;5:715–23. https://doi.org/10. 1016/j.jchf.2017.06.016 903. Pearse SG, Cowie MR. Sleep-disordered breathing in heart failure. Eur J Heart Fail 2016;18:353–61. https://doi.org/10.1002/ejhf.492 904. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095–105. https://doi.org/10.1056/ NEJMoa1506459 905. Bradley TD, Logan AG, Lorenzi Filho G, Kimoff RJ, Duran Cantolla J, Arzt M, et al. Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial. Lancet Respir Med 2024;12:153–66. https://doi.org/10.1016/S2213- 2600(23)00374-0 906. Baumert M, Immanuel S, McKane S, Linz D. Transvenous phrenic nerve stimulation for the treatment of central sleep apnea reduces episodic hypoxemic burden. Int J Cardiol 2023;378:89–95. https://doi.org/10.1016/j. ijcard.2023.02.041 907. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet 2016;388:974–82. https://doi.org/10.1016/S0140- 6736(16)30961-8 908. Costanzo MR, Ponikowski P, Coats A, Javaheri S, Augostini R, Goldberg LR, et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. Eur J Heart Fail 2018;20:1746–54. https://doi.org/10. 1002/ejhf.1312 909. Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of anxiety in samples of patients with heart failure: meta-analysis. J Cardiovasc Nurs 2016;31:367–79. https://doi.org/10.1097/JCN. 0000000000000265 910. Angermann CE, Ertl G. Depression, anxiety, and cognitive impairment: comorbid mental health disorders in heart failure. Curr Heart Fail Rep 2018; 15:398–410. https://doi.org/10.1007/s11897-018-0414-8 911. Sbolli M, Fiuzat M, Cani D, O’Connor CM. Depression and heart failure: the lonely comorbidity. Eur J Heart Fail 2020;22:2007–17. https://doi.org/10. 1002/ejhf.1865 912. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:1827–45. https:// doi.org/10.1016/j.jacc.2019.01.041 913. Massussi M, Bellicini MG, Adamo M, Pilotto A, Metra M, Padovani A, et al. Connecting the dots: a narrative review of the relationship between heart failure and cognitive impairment. ESC Heart Fail 2025;12:1119–31. https:// doi.org/10.1002/ehf2.15144 914. Balata M, Gbreel MI, Elrashedy AA, Westenfeld R, Pfister R, Zimmer S, et al. Clinical effects of cognitive behavioral therapy in heart failure patients: a meta-analysis of randomized controlled trials. BMC Complement Med Ther 2023;23:280. https://doi.org/10.1186/s12906-023-04117-2 915. Chernoff RA, Messineo G, Kim S, Pizano D, Korouri S, Danovitch I, et al. Psychosocial interventions for patients with heart failure and their impact on depression, anxiety, quality of life, morbidity, and mortality: a systematic review and meta-analysis. Psychosom Med 2022;84:560–80. https://doi.org/ 10.1097/PSY.0000000000001073 916. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56: 692–99. https://doi.org/10.1016/j.jacc.2010.03.068 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026